Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Guangxi University of Chinese Medicine, 13 Wuhe Road, Qingxiu District, Nanning 530200, China.
CAS Key Laboratory of Tropical Marine Bio-Resources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China.
Molecules. 2022 May 26;27(11):3446. doi: 10.3390/molecules27113446.
Prostate cancer is a common cancer in elderly males. Significant progress has been made in the drug therapies for prostate cancer in recent years. However, side effects are still problems that have not been overcome by the currently used anti-prostate cancer drugs. Novel technologies can be applied to reduce or even eliminate the side effects of drugs. An aptamer may be a sequence of nucleic acids or peptides that can specifically recognize proteins or cells. Taking advantage of this feature, scientists have designed aptamer-drug delivery systems for the development of anti-prostate cancer agents. Theoretically, these aptamer-drug delivery systems can specifically recognize prostate cancer cells and then induce cell death without attacking normal cells. We collected the relevant literature in this field and found that at least nine compounds have been prepared as aptamer-drug delivery systems to evaluate their precise anti-prostate cancer effects. However, the currently studied aptamer-drug delivery systems have not yet entered the market due to defects. Here, we analyze the published data, summarize the characteristics of these delivery systems, and propose ways to promote their application, thus promoting the development of the aptamer-drug delivery systems against prostate cancer.
前列腺癌是老年男性中常见的癌症。近年来,前列腺癌的药物治疗取得了重大进展。然而,副作用仍然是目前使用的抗前列腺癌药物尚未克服的问题。新技术可用于减少甚至消除药物的副作用。适体可能是一种可以特异性识别蛋白质或细胞的核酸或肽序列。利用这一特性,科学家们设计了适体-药物传递系统,用于开发抗前列腺癌药物。从理论上讲,这些适体-药物传递系统可以特异性识别前列腺癌细胞,然后诱导细胞死亡而不攻击正常细胞。我们收集了该领域的相关文献,发现至少有九种化合物已被制备为适体-药物传递系统,以评估其精确的抗前列腺癌作用。然而,由于缺陷,目前研究的适体-药物传递系统尚未进入市场。在这里,我们分析已发表的数据,总结这些传递系统的特点,并提出促进其应用的方法,从而推动针对前列腺癌的适体-药物传递系统的发展。